Article
The issue
CMS has proposed a rule, CMS-4215-P, that would write the Medicare Drug Price Negotiation Program into regulation. A key question is how the negotiated price, known as the maximum fair price, reaches the hospitals and pharmacies that dispense the drug. One option is a point-of-sale price. The other is a retrospective approach, in which a provider buys the drug at a higher price and later receives a rebate or reconciliation from the manufacturer.
The AHA’s letter, signed by executive vice president Stacey Hughes, urged CMS to require the point-of-sale approach and to remove options that let manufacturers meet their obligations through rebates or after-the-fact reconciliation.
Why hospitals care
The AHA made three main arguments:
- Cash flow. Under a rebate model, hospitals finance large drug purchases while they wait for payment. The AHA said this is hardest on rural, critical access, sole community and safety-net hospitals.
- Administrative burden. Hospitals have dealt with manual processes, IT spending and data mismatches while handling negotiated prices in 2026. Manufacturer-specific approaches would multiply that work.
- 340B. The AHA warned that accepting retrospective delivery here could become a foundation for moving 340B from upfront discounts to rebates. It noted that CMS’s own estimate put the cost of a separate proposed 340B rebate approach at more than half a billion dollars a year for covered entities, a figure the AHA believes is too low.
The AHA also asked for a single national standard that coordinates with 340B, minimal provider reporting and no duplicative tracking systems. It argued that the statute does not prescribe a payment mechanism, so CMS has room to require the prospective approach.
What leaders should do
The number of drugs subject to negotiated prices will keep growing, so the way those prices flow will matter more to pharmacy budgets each year.
- Measure the float. Calculate how long your organization waits for negotiated-price reimbursement today and what that costs in working capital.
- Map the work. Count staff hours and systems involved in tracking and reconciling these claims.
- Link to 340B strategy. Model what a broader shift to rebates would mean for your 340B savings and for the programs those savings support.
- Brief the board. Treat drug pricing mechanics as a finance risk, not just a pharmacy operations issue.
Archive entry for Aug 17, 2026, added Nov. 11, 2026.